[go: up one dir, main page]

DE10346134A1 - Neue Verwendung, pharmazeutische Zubereitungen sowie Verfahren zu deren Herstellung - Google Patents

Neue Verwendung, pharmazeutische Zubereitungen sowie Verfahren zu deren Herstellung Download PDF

Info

Publication number
DE10346134A1
DE10346134A1 DE10346134A DE10346134A DE10346134A1 DE 10346134 A1 DE10346134 A1 DE 10346134A1 DE 10346134 A DE10346134 A DE 10346134A DE 10346134 A DE10346134 A DE 10346134A DE 10346134 A1 DE10346134 A1 DE 10346134A1
Authority
DE
Germany
Prior art keywords
production
concentrated
mercatoethanesulfonate
sodium
stable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE10346134A
Other languages
English (en)
Inventor
Berthold Roessler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter Healthcare SA
Original Assignee
Baxter Healthcare SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Healthcare SA filed Critical Baxter Healthcare SA
Priority to DE10346134A priority Critical patent/DE10346134A1/de
Publication of DE10346134A1 publication Critical patent/DE10346134A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Die Erfindung betrifft die Verwendung von Mercaptoethansulfonat-Natrium (Mesna) zur Erhöhung der Löslichkeit von Ifosfamid in lagerstabilen konzentrierten bzw. hochkonzentrierten (übersättigten) wasserhaltigen pharmazeutischen Zubereitungen, lagerstabile konzentrierte bzw. hochkonzentrierte (übersättigte) wasserhaltige pharmazeutische Ifosfamid-Zubereitungen zur parenteralen Anwendung sowie Verfahren zu deren Herstellung.
DE10346134A 2003-10-01 2003-10-01 Neue Verwendung, pharmazeutische Zubereitungen sowie Verfahren zu deren Herstellung Withdrawn DE10346134A1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE10346134A DE10346134A1 (de) 2003-10-01 2003-10-01 Neue Verwendung, pharmazeutische Zubereitungen sowie Verfahren zu deren Herstellung

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10346134A DE10346134A1 (de) 2003-10-01 2003-10-01 Neue Verwendung, pharmazeutische Zubereitungen sowie Verfahren zu deren Herstellung

Publications (1)

Publication Number Publication Date
DE10346134A1 true DE10346134A1 (de) 2005-04-21

Family

ID=34353311

Family Applications (1)

Application Number Title Priority Date Filing Date
DE10346134A Withdrawn DE10346134A1 (de) 2003-10-01 2003-10-01 Neue Verwendung, pharmazeutische Zubereitungen sowie Verfahren zu deren Herstellung

Country Status (1)

Country Link
DE (1) DE10346134A1 (de)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3907079A1 (de) * 1988-03-19 1989-09-28 Asta Pharma Ag Ifosfamid-mesna-lyophilisat und verfahren zu dessen herstellung
WO1999018973A2 (de) * 1997-10-13 1999-04-22 Stada Arzneimittel Ag Flüssige darreichungsformen oxazaphosphorinhaltiger pharmazeutischer produkte
WO2004022699A2 (en) * 2002-09-05 2004-03-18 Bharat Serums And Vaccines Ltd. Liquid stable composition of oxazaphosphorine with mesna

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3907079A1 (de) * 1988-03-19 1989-09-28 Asta Pharma Ag Ifosfamid-mesna-lyophilisat und verfahren zu dessen herstellung
WO1999018973A2 (de) * 1997-10-13 1999-04-22 Stada Arzneimittel Ag Flüssige darreichungsformen oxazaphosphorinhaltiger pharmazeutischer produkte
WO2004022699A2 (en) * 2002-09-05 2004-03-18 Bharat Serums And Vaccines Ltd. Liquid stable composition of oxazaphosphorine with mesna

Similar Documents

Publication Publication Date Title
Gilad et al. Accelerated functional recovery and neuroprotection by agmatine after spinal cord ischemia in rats
CY1123084T1 (el) Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι
DK1317419T3 (da) Cyanophenoxycarboxylsyre-forbindelser og sammensætninger til at levere aktive midler
AP1666A (en) Quinolinone derivatives as tyrosine kinase inhibitors.
ATE269089T1 (de) Verwendung von vitamin d derivaten zur verstärkung der wirkung von zytotoxischen stoffen
NL7906620A (nl) Aminozuuroplossingen voor kankerpatieenten.
YU44404A (sh) Postupak za identifikovanje ciljnih enzima tumora
JP2010513487A5 (de)
RU2007119724A (ru) Композиции, содержащие эктинэсайдин и дисахарид
US20050222038A1 (en) Protection against ischemia and reperfusion injury
EP1177791A3 (de) Verwendung von Glykogen-Phosphorylase-Hemmer zur Hemmung des Tumorwachstums
IL140848A0 (en) Treatment regimen for administration of phenylacetylacetylglutamine, phenylacetylisoglutamine and/or phenylacetate
ES2267591T3 (es) Combinaciones farmaceuticas que comprenden un antagonista del receptor p2t y melagatran.
GB2352972A (en) Use of dexmedetomidine for icu sedation
MXPA02011389A (es) Forma de administracion farmaceutica para peptidos, procedimiento para su preparacion y aplicacion.
PL350660A1 (en) Synergistic inhibition of viral replication by long−chain hydrocarbons and nucleoside analogs
EP1275646A4 (de) Indolylpyrrol-derivate und zelltod-inhibitoren
MX2010003594A (es) Formas cristalinas de sal sodica de dmxaa.
DE10346134A1 (de) Neue Verwendung, pharmazeutische Zubereitungen sowie Verfahren zu deren Herstellung
Kondo et al. Effects of intracerebroventricular administration of prostaglandins I2, E2, F2α and indomethacin on blood pressure in the rat
TW201023879A (en) Method of inhibiting and/or rescuing cell terminal differentiation, and composition for treating and/or inhibiting arthritis
BRPI0606119A2 (pt) preparações injetáveis de diclofenaco e seus sais farmaceuticamente aceitáveis
WO2001056551A2 (en) Method and formulation for treatment of vasoconstriction
Levy et al. Effect of ethionine on the free amino acids in liver of tumorous and nontumorous rats
ES2317913T3 (es) Tratamiento antitumoral combinado que comprende un derivado de la distamicina sustituida por acriloilo y un antimetabolito.

Legal Events

Date Code Title Description
OM8 Search report available as to paragraph 43 lit. 1 sentence 1 patent law
8110 Request for examination paragraph 44
8128 New person/name/address of the agent

Representative=s name: MUELLER-BORE & PARTNER, PATENTANWAELTE, EUROPEAN P

R119 Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee

Effective date: 20130501